U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Glucose transport disorder

MedGen UID:
1842427
•Concept ID:
C5389835
•
Disease or Syndrome
Synonyms: glucose transport disorder; inborn error of glucose transport; rare inborn error of glucose transport
 
Monarch Initiative: MONDO:0019226
Orphanet: ORPHA79178

Definition

An inherited metabolic disease that is has its basis in the disruption of glucose transport. [from MONDO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGlucose transport disorder

Professional guidelines

PubMed

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW
Circulation 2022 May 3;145(18):e876-e894. Epub 2022 Apr 1 doi: 10.1161/CIR.0000000000001062. PMID: 35363500
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW
Circulation 2022 May 3;145(18):e895-e1032. Epub 2022 Apr 1 doi: 10.1161/CIR.0000000000001063. PMID: 35363499
Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State.
Fayfman M, Pasquel FJ, Umpierrez GE
Med Clin North Am 2017 May;101(3):587-606. doi: 10.1016/j.mcna.2016.12.011. PMID: 28372715Free PMC Article

Recent clinical studies

Etiology

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M, Sardu C, Sasso FC
Int J Mol Sci 2022 Mar 26;23(7) doi: 10.3390/ijms23073651. PMID: 35409011Free PMC Article
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ, Day C, Bellary S
Curr Diab Rep 2022 Jan;22(1):39-52. Epub 2022 Feb 3 doi: 10.1007/s11892-021-01442-z. PMID: 35113333Free PMC Article
The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V, Thomson SC
Nat Rev Nephrol 2020 Jun;16(6):317-336. Epub 2020 Mar 9 doi: 10.1038/s41581-020-0256-y. PMID: 32152499Free PMC Article
Fructose metabolism and metabolic disease.
Hannou SA, Haslam DE, McKeown NM, Herman MA
J Clin Invest 2018 Feb 1;128(2):545-555. doi: 10.1172/JCI96702. PMID: 29388924Free PMC Article
GLUT2, glucose sensing and glucose homeostasis.
Thorens B
Diabetologia 2015 Feb;58(2):221-32. Epub 2014 Nov 25 doi: 10.1007/s00125-014-3451-1. PMID: 25421524

Diagnosis

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium
Lancet 2022 Nov 19;400(10365):1788-1801. Epub 2022 Nov 6 doi: 10.1016/S0140-6736(22)02074-8. PMID: 36351458Free PMC Article
Potential of Creatine in Glucose Management and Diabetes.
Solis MY, Artioli GG, Gualano B
Nutrients 2021 Feb 9;13(2) doi: 10.3390/nu13020570. PMID: 33572228Free PMC Article
Euglycemic diabetic ketoacidosis.
Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A
Eur J Intern Med 2019 May;63:9-14. Epub 2019 Mar 23 doi: 10.1016/j.ejim.2019.03.014. PMID: 30910328
Euglycemic Diabetic Ketoacidosis: A Review.
Modi A, Agrawal A, Morgan F
Curr Diabetes Rev 2017;13(3):315-321. doi: 10.2174/1573399812666160421121307. PMID: 27097605
GLUT2, glucose sensing and glucose homeostasis.
Thorens B
Diabetologia 2015 Feb;58(2):221-32. Epub 2014 Nov 25 doi: 10.1007/s00125-014-3451-1. PMID: 25421524

Therapy

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium
Lancet 2022 Nov 19;400(10365):1788-1801. Epub 2022 Nov 6 doi: 10.1016/S0140-6736(22)02074-8. PMID: 36351458Free PMC Article
Potential of Creatine in Glucose Management and Diabetes.
Solis MY, Artioli GG, Gualano B
Nutrients 2021 Feb 9;13(2) doi: 10.3390/nu13020570. PMID: 33572228Free PMC Article
The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V, Thomson SC
Nat Rev Nephrol 2020 Jun;16(6):317-336. Epub 2020 Mar 9 doi: 10.1038/s41581-020-0256-y. PMID: 32152499Free PMC Article
Euglycemic diabetic ketoacidosis.
Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A
Eur J Intern Med 2019 May;63:9-14. Epub 2019 Mar 23 doi: 10.1016/j.ejim.2019.03.014. PMID: 30910328
Euglycemic Diabetic Ketoacidosis: A Review.
Modi A, Agrawal A, Morgan F
Curr Diabetes Rev 2017;13(3):315-321. doi: 10.2174/1573399812666160421121307. PMID: 27097605

Prognosis

Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer.
Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, Wang H, He J, Zhu Y, Ju Y, Zhang Y, Guo S, Yang W, Yin H, Chen L, Gao D, Jin G
Cell Rep Med 2023 Sep 19;4(9):101162. Epub 2023 Aug 18 doi: 10.1016/j.xcrm.2023.101162. PMID: 37597521Free PMC Article
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
Scheen AJ, Bonnet F
Diabetes Metab 2023 Mar;49(2):101419. Epub 2023 Jan 11 doi: 10.1016/j.diabet.2023.101419. PMID: 36640828
m(6)A-dependent glycolysis enhances colorectal cancer progression.
Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X, Zhang X, Cao Y, Ma D, Zhu X, Zhang Y, Fang JY, Chen H, Hong J
Mol Cancer 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w. PMID: 32245489Free PMC Article
The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V, Thomson SC
Nat Rev Nephrol 2020 Jun;16(6):317-336. Epub 2020 Mar 9 doi: 10.1038/s41581-020-0256-y. PMID: 32152499Free PMC Article
Crystal structure of the human glucose transporter GLUT1.
Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, Yan N
Nature 2014 Jun 5;510(7503):121-5. Epub 2014 May 18 doi: 10.1038/nature13306. PMID: 24847886

Clinical prediction guides

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M, Sardu C, Sasso FC
Int J Mol Sci 2022 Mar 26;23(7) doi: 10.3390/ijms23073651. PMID: 35409011Free PMC Article
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ, Day C, Bellary S
Curr Diab Rep 2022 Jan;22(1):39-52. Epub 2022 Feb 3 doi: 10.1007/s11892-021-01442-z. PMID: 35113333Free PMC Article
Aralar Sequesters GABA into Hyperactive Mitochondria, Causing Social Behavior Deficits.
Kanellopoulos AK, Mariano V, Spinazzi M, Woo YJ, McLean C, Pech U, Li KW, Armstrong JD, Giangrande A, Callaerts P, Smit AB, Abrahams BS, Fiala A, Achsel T, Bagni C
Cell 2020 Mar 19;180(6):1178-1197.e20. doi: 10.1016/j.cell.2020.02.044. PMID: 32200800
The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V, Thomson SC
Nat Rev Nephrol 2020 Jun;16(6):317-336. Epub 2020 Mar 9 doi: 10.1038/s41581-020-0256-y. PMID: 32152499Free PMC Article
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ
Circulation 2016 Sep 6;134(10):752-72. Epub 2016 Jul 28 doi: 10.1161/CIRCULATIONAHA.116.021887. PMID: 27470878

Recent systematic reviews

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC 3rd, Mustafa RA, Agarwal A, Zou X, Mao Y, Asadollahifar A, Chowdhury SR, Zhai C, Gupta S, Gao Y, Lima JP, Numata K, Qiao Z, Fan Q, Yang Q, Jin Y, Ge L, Yang Q, Zhu H, Yang F, Chen Z, Lu X, He S, Chen X, Lyu X, An X, Chen Y, Hao Q, Standl E, Siemieniuk R, Agoritsas T, Tian H, Li S
BMJ 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068. PMID: 37024129Free PMC Article
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium
Lancet 2022 Nov 19;400(10365):1788-1801. Epub 2022 Nov 6 doi: 10.1016/S0140-6736(22)02074-8. PMID: 36351458Free PMC Article
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM
BMJ 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573. PMID: 33441402Free PMC Article
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
Lancet 2019 Jan 5;393(10166):31-39. Epub 2018 Nov 10 doi: 10.1016/S0140-6736(18)32590-X. PMID: 30424892
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S
Cochrane Database Syst Rev 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2. PMID: 30246878Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On
    • Glucose transport disorder
      Glucose transport disorder
      MedGen
    • Craniofacial Dysostosis
      Craniofacial Dysostosis
      Autosomal dominant CRANIOSYNOSTOSIS with shallow ORBITS; EXOPHTHALMOS; and maxillary hypoplasia.<br/>
      MeSH
    • Receptors, Histamine H2
      Receptors, Histamine H2
      A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine H2 receptors act via G-proteins to stimulate ADENYLYL CYCLASES. Among the many...<br/>Year introduced: 1987(1977)
      MeSH
    • Receptors, Histamine H1
      Receptors, Histamine H1
      A class of histamine receptors discriminated by their pharmacology and mode of action. Most histamine H1 receptors operate through the inositol phosphate/diacylglycerol second...<br/>Year introduced: 1989(1977)
      MeSH
    • Chemokine CCL26
      Chemokine CCL26
      A C-C chemokine expressed by all tissues that functions as a chemoattractant for EOSINOPHILS and BASOPHILS. It binds to the CCR3 RECEPTOR.<br/>Year introduced: 2018
      MeSH

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...